|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15171518151915201521152215231524152515261527...15771578» |
- ||||| Lartruvo (olaratumab) / Eli Lilly
Enrollment closed, Metastases: ANNOUNCE: A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 2, 2016
P3, N=460, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment closed, Enrollment change, Metastases: A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Aug 2, 2016
P3, N=16, Active, not recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=141 --> 16
- Votrient (pazopanib) / Novartis, BeiGene, sapanisertib (CB-228) / Calithera
Metastases: Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Aug 1, 2016
P2, N=148, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=141 --> 16 Recruiting --> Suspended
- Enrollment change, Trial termination: Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 30, 2016
P2, N=11, Terminated, Sponsor: Centre Oscar Lambret
Recruiting --> Suspended N=240 --> 11 | Active, not recruiting --> Terminated; lack of enrollment
- Enrollment closed, Enrollment change, Trial primary completion date: ANGIHE: Identification, Molecular Epidemiology Angiosarcoma of the Liver France (clinicaltrials.gov) - Jul 30, 2016
P=N/A, N=9, Active, not recruiting, Sponsor: Centre Oscar Lambret
N=240 --> 11 | Active, not recruiting --> Terminated; lack of enrollment Recruiting --> Active, not recruiting | N=30 --> 9 | Trial primary completion date: Jun 2016 --> Sep 2016
- Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Jul 29, 2016
P1, N=18, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=30 --> 9 | Trial primary completion date: Jun 2016 --> Sep 2016 Trial primary completion date: Jul 2016 --> Dec 2016
- Keytruda (pembrolizumab) / Merck (MSD), Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date, PD(L)-1 Biomarker, Metastases: Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov) - Jul 29, 2016
P1, N=36, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2016 --> Dec 2016 Trial primary completion date: Jul 2016 --> Apr 2017
- Trial primary completion date, IO biomarker, Surgery, Metastases: TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 29, 2016
P1, N=17, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jul 2016 --> Apr 2017 Trial primary completion date: Sep 2016 --> Mar 2017
- Trial primary completion date: Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=2000, Recruiting, Sponsor: D. Ashley Hill, M.D.
Trial primary completion date: Sep 2016 --> Mar 2017 Trial primary completion date: Dec 2016 --> Dec 2018
- ||| Stivarga (regorafenib) / Bayer
Enrollment closed, Trial primary completion date, Metastases: REGO-SARC: Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 29, 2016
P2, N=196, Active, not recruiting, Sponsor: Centre Oscar Lambret
Trial primary completion date: Dec 2016 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Mar 2017
- New P1/2 trial, Surgery: Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma (clinicaltrials.gov) - Jul 29, 2016
P1/2, N=30, Recruiting, Sponsor: Fuda Cancer Hospital, Guangzhou
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Enrollment closed, Metastases: Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 29, 2016
P2, N=53, Active, not recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Mar 2017 Not yet recruiting --> Active, not recruiting
- |||||||||| crenolanib (ARO-002) / AROG
New P3 trial, Stroma, Metastases: Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST (clinicaltrials.gov) - Jul 28, 2016
P3, N=120, Not yet recruiting, Sponsor: Arog Pharmaceuticals, Inc.
- sunitinib / Generic mfg.
Trial primary completion date, Metastases: Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (clinicaltrials.gov) - Jul 28, 2016
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Jan 2017
- efatutazone (CS-7017) / Daiichi Sankyo
Trial suspension, Surgery: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 28, 2016
P2, N=36, Suspended, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jun 2016 --> Jan 2017 Active, not recruiting --> Suspended
- | Verzenio (abemaciclib) / Eli Lilly
New P2 trial: Study of Abemaciclib in Dedifferentiated Liposarcoma (clinicaltrials.gov) - Jul 27, 2016
P2, N=30, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung (clinicaltrials.gov) - Jul 26, 2016
P2, N=35, Recruiting, Sponsor: Vector Oncology
Active, not recruiting --> Suspended Trial primary completion date: Jun 2017 --> Jun 2018
- cyclophosphamide / Generic mfg., celecoxib oral / Generic mfg.
Trial termination, Tumor cell, Metastases: Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal (clinicaltrials.gov) - Jul 26, 2016
P1, N=41, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2017 --> Jun 2018 Completed --> Terminated
- SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax, Roswell Park Comprehensive Cancer Center
Trial completion: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Jul 26, 2016
P1, N=9, Completed, Sponsor: Roswell Park Cancer Institute
Completed --> Terminated Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: SIKO: Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe (clinicaltrials.gov) - Jul 25, 2016
P=N/A, N=1024, Active, not recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017
- Onureg (azacitidine oral) / BMS, Istodax (romidepsin) / Astellas, BMS
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma (clinicaltrials.gov) - Jul 25, 2016
P1, N=18, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Active, not recruiting | N=39 --> 18 | Trial primary completion date: Mar 2017 --> Mar 2016
- LPX EWS/FL1 T1 / Gradalis
Trial initiation date, Trial primary completion date, Metastases: Pbi-shRNA (clinicaltrials.gov) - Jul 25, 2016
P1, N=22, Not yet recruiting, Sponsor: Strike Bio, Inc.
Recruiting --> Active, not recruiting | N=39 --> 18 | Trial primary completion date: Mar 2017 --> Mar 2016 Initiation date: May 2016 --> Sep 2016 | Trial primary completion date: May 2018 --> Sep 2018
- Trial primary completion date: Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues (SkinAge). (clinicaltrials.gov) - Jul 24, 2016
P=N/A, N=60, Recruiting, Sponsor: Centre Oscar Lambret
Initiation date: May 2016 --> Sep 2016 | Trial primary completion date: May 2018 --> Sep 2018 Trial primary completion date: Jun 2016 --> Jun 2017
- Trial primary completion date, HEOR, Metastases: Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease (clinicaltrials.gov) - Jul 24, 2016
P=N/A, N=100, Recruiting, Sponsor: Duke University
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Sep 2016 --> Sep 2017
- |||| Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: ANNOUNCE: A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 23, 2016
P3, N=460, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Apr 2019 --> Sep 2018
- Trial primary completion date, Surgery, Stroma, Biopsy: Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy (clinicaltrials.gov) - Jul 23, 2016
P=N/A, N=1000, Recruiting, Sponsor: University of Chicago
Trial primary completion date: Apr 2019 --> Sep 2018 Trial primary completion date: Oct 2016 --> Oct 2017
- ||| alisertib (MLN8237) / Puma
Enrollment closed, Enrollment change, Trial primary completion date: Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) - Jul 23, 2016
P2, N=112, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Oct 2016 --> Oct 2017 Completed --> Active, not recruiting | N=228 --> 112 | Trial primary completion date: Jan 2014 --> Dec 2015
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Enrollment open: TrObs: Retrospective Study of Trabectedin in Soft Tissue Sarcomas (clinicaltrials.gov) - Jul 23, 2016
P=N/A, N=900, Recruiting, Sponsor: Italian Sarcoma Group
Completed --> Active, not recruiting | N=228 --> 112 | Trial primary completion date: Jan 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- celecoxib oral / Generic mfg.
New P1 trial: Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy (clinicaltrials.gov) - Jul 21, 2016
P1, N=46, Recruiting, Sponsor: National Cancer Institute (NCI)
- Trial primary completion date: The Oncopanel Pilot (TOP) Study (clinicaltrials.gov) - Jul 21, 2016
P=N/A, N=432, Active, not recruiting, Sponsor: British Columbia Cancer Agency
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Sep 2016
- | Zolinza (vorinostat) / Merck (MSD)
P1/2 data, Phase classification, Combination therapy, Metastases: GemTax: Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma (clinicaltrials.gov) - Jul 21, 2016
P1b/2, N=67, Recruiting, Sponsor: Melissa Burgess, MD
Trial primary completion date: Jun 2016 --> Sep 2016 Phase classification: P1/2 --> P1b/2
- Enrollment open: Optional Sub-study to Intraoperative Imaging With ICG Registry (clinicaltrials.gov) - Jul 20, 2016
P=N/A, N=500, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Phase classification: P1/2 --> P1b/2 Not yet recruiting --> Recruiting
- || New P3 trial: ETOILE: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors (clinicaltrials.gov) - Jul 20, 2016
P3, N=250, Not yet recruiting, Sponsor: Hospices Civils de Lyon
- || Kisqali (ribociclib) / Novartis, siremadlin (HDM201) / Novartis
Combination therapy: Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=84, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2017 --> Mar 2018
- || Tibsovo (ivosidenib) / Servier
Trial primary completion date, Metastases: Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation (clinicaltrials.gov) - Jul 19, 2016
P1, N=145, Recruiting, Sponsor: Agios Pharmaceuticals, Inc.
Trial primary completion date: Sep 2017 --> Mar 2018 Trial primary completion date: May 2016 --> Aug 2017
- Trial primary completion date: MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=15, Recruiting, Sponsor: Christie Hospital NHS Foundation Trust
Trial primary completion date: May 2016 --> Aug 2017 Trial primary completion date: Feb 2016 --> Sep 2016
- Kisqali (ribociclib) / Novartis
Trial primary completion date: Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma (clinicaltrials.gov) - Jul 19, 2016
P1, N=32, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2016 --> Sep 2016 Trial primary completion date: Mar 2016 --> Dec 2016
- imatinib / Generic mfg.
Trial primary completion date, Metastases: Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI (clinicaltrials.gov) - Jul 19, 2016
P2, N=44, Recruiting, Sponsor: Asan Medical Center
Trial primary completion date: Mar 2016 --> Dec 2016 Trial primary completion date: Mar 2016 --> Dec 2016
- Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical: Tocilizumab for KSHV-Associated Multicentric Castleman Disease (clinicaltrials.gov) - Jul 19, 2016
P2, N=17, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2016 --> Dec 2016 Trial primary completion date: Jul 2016 --> Jul 2020
- Trial primary completion date: Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=100, Recruiting, Sponsor: Stanford University
Trial primary completion date: Jul 2016 --> Jul 2020 Trial primary completion date: Dec 2015 --> Jan 2099
- Recentin (cediranib) / AstraZeneca
Trial primary completion date: Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Jul 19, 2016
P2, N=73, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Jan 2099 Trial primary completion date: Jul 2017 --> Jul 2016
- Trial initiation date: PRO-YOU: Programs To Support You During Chemotherapy (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=60, Not yet recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Jul 2017 --> Jul 2016 Initiation date: Aug 2015 --> Jul 2016
- Enrollment closed: Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma (clinicaltrials.gov) - Jul 19, 2016
P1, N=54, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Initiation date: Aug 2015 --> Jul 2016 Completed --> Active, not recruiting
- Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date, Combination therapy, Surgery, Stroma, Metastases: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (clinicaltrials.gov) - Jul 15, 2016
P1, N=39, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting N=29 --> 39 | Trial primary completion date: Dec 2015 --> Dec 2016
- New trial, MRI: Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT) (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=70, Recruiting, Sponsor: University of Genova
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Tumor mutational burden: SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=334, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Biomarker, Trial completion, Trial primary completion date: Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=1650, Completed, Sponsor: Children's Oncology Group
N=29 --> 39 | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
- | Biomarker, Trial completion, Trial primary completion date, IO biomarker: Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=49, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: May 2016 --> Jul 2014
- | Trial completion, Trial primary completion date: Studying Gene Expression in Samples From Patients With Rhabdoid Tumors (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=25, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: May 2016 --> Jul 2014 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
- | sirolimus / Generic mfg.
Trial completion, Trial primary completion date: Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma (clinicaltrials.gov) - Jul 14, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Oct 2013